AMG 133
Sponsors
Amgen Inc., Amgen
Conditions
"Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweightChronic Weight ManagementHealthy ParticipantsHepatic ImpairmentModerate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesityObesityOverweight
Phase 1
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
CompletedNCT05056246
Start: 2021-09-10End: 2022-04-08Updated: 2025-02-25
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
CompletedNCT06976372
Start: 2024-08-20End: 2024-12-27Updated: 2025-10-08
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
CompletedNCT07310563
Start: 2024-12-10End: 2025-05-09Updated: 2025-12-30
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
CompletedNCT07428525
Start: 2025-03-14End: 2026-02-26Updated: 2026-03-11
The Effect of AMG 133 on Gastric Emptying
CompletedNCT07429032
Start: 2025-04-17End: 2025-11-26Updated: 2026-02-24
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
CompletedNCT07429045
Start: 2025-03-11End: 2025-11-21Updated: 2026-02-24
Phase 2
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus.
CompletedCTIS2023-510470-13-00
Start: 2023-03-10End: 2025-10-14Target: 135Updated: 2026-01-26
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Active, not recruitingCTIS2024-513539-25-00
Start: 2024-11-22Target: 169Updated: 2025-09-25
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)
Active, not recruitingCTIS2024-515524-36-00
Start: 2025-05-30Target: 1050Updated: 2025-09-18
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
Active, not recruitingCTIS2024-515523-11-00
Start: 2025-06-09Target: 404Updated: 2025-09-25
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
RecruitingCTIS2024-516652-18-00
Start: 2025-10-10Target: 5564Updated: 2025-11-24
A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with
Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)
Not yet recruitingCTIS2025-522699-94-00
Target: 97Updated: 2026-01-30
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
Not yet recruitingCTIS2025-522703-14-00
Target: 45Updated: 2026-02-10